This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Diabetes & metabolism, 45(5), 409-418
Citation
Aroda, V R; Ahmann, A; Cariou, B; Chow, F; Davies, M J; Jódar, E; Mehta, R; Woo, V; Lingvay, I. (2019). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.. Diabetes & metabolism, 45(5), 409-418. https://doi.org/10.1016/j.diabet.2018.12.001